What question did this study set out to answer?

This research aims to validate the SET2,3 index as a prognostic biomarker for disease-free survival in Latin American breast cancer patients.

February 19, 2026Clinical Cancer Research

Abstract PS3-09-21: Evaluation of Sensitivity to Endocrine Therapy (SET) as a Prognostic Biomarker in the Latin American Breast Cancer Cohort Study

View Full Paper

Ask AI

Bookmark

This research aims to validate the SET2,3 index as a prognostic biomarker for disease-free survival in Latin American breast cancer patients.
Retrospective analysis of clinical and pathological data from a multi-country Latin American breast cancer cohort.
Characterization of tumor subtypes using PAM50 classification, Ki67%, and immunohistochemical analysis for hormone receptor status.
Measurement of SET2,3 index using the QuantiGene Plex Assay on archival tumor tissue samples, blinded to clinical outcomes.
Comparison of disease-free survival across patient subgroups using log-rank tests and hazard ratio estimation through Cox proportional hazards models.
A total of 292 patients included, with 38 disease-free survival events over a median follow-up of 7.15 years.
SET2,3 index significantly associated with longer disease-free survival (HR 3.45; p < 0.001).
In patients undergoing primary surgery, lower SET2,3 index correlated with worse outcomes (HR 3.20; p = 0.002).
SET2,3 index also prognostic for those receiving adjuvant chemotherapy and endocrine therapy alone, indicating its robust predictive capability.
SETER/PR index significantly prognostic for patients receiving adjuvant endocrine therapy (HR 0.31; p < 0.001).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Clinical evaluation of the SET2,3 index predicts disease-free survival in hormone receptor-positive breast cancer, suggesting its utility in treatment planning.

Cite This Study

Canola et al. (2026) studied this question.

synapsesocial.com/papers/6996a84cecb39a600b3eed06 https://doi.org/10.1158/1557-3265.sabcs25-ps3-09-21

View Full Paper

Ask AI

Bookmark

Implication

Clinical evaluation of the SET2,3 index predicts disease-free survival in hormone receptor-positive breast cancer, suggesting its utility in treatment planning.

Abstract PS3-09-21: Evaluation of Sensitivity to Endocrine Therapy (SET) as a Prognostic Biomarker in the Latin American Breast Cancer Cohort Study

Key Points

Discussion

Implication

Cite This Study

Abstract PS3-09-21: Evaluation of Sensitivity to Endocrine Therapy (SET) as a Prognostic Biomarker in the Latin American Breast Cancer Cohort Study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider